Shenandoah Telecommunications Co の最大収益セグメントは Residential Small and Medium Business - Incumbent Broadband Markets で、最新の利益発表における収益は 177,485,000 です。地域別に見ると、United States が Shenandoah Telecommunications Co の主要市場であり、収益は 328,058,000 です。
Avalon Globocare Corp은 수익성이 있나요?
いいえ, 최신 재무제표에 따르면 Shenandoah Telecommunications Co의 순損失은 $0입니다.
Avalon Globocare Corp에 부채가 있나요?
いいえ, Shenandoah Telecommunications Co의 부채는 0입니다.
Avalon Globocare Corp의 발행 주식은 몇 주인가요?
Shenandoah Telecommunications Co의 총 발행 주식은 0주입니다.
主要データ
前終値
$0.194
始値
$0.19
当日レンジ
$0.19 - $0.2254
52週レンジ
$0.21 - $4.74
取引高
--
平均取引高
1.3M
配当利回り
--
1株当たり利益(TTM)
-8.23
時価総額
$2.6M
ALBTとは何ですか?
Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. The company is headquartered in Freehold, New Jersey and currently employs 2 full-time employees. The company went IPO on 2016-02-22. The firm operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The firm is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.